NRXP Stock Overview
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.
NRx Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.15|
|52 Week High||US$10.39|
|52 Week Low||US$0.49|
|1 Month Change||41.98%|
|3 Month Change||66.02%|
|1 Year Change||-82.96%|
|3 Year Change||-89.05%|
|5 Year Change||n/a|
|Change since IPO||-88.02%|
Recent News & Updates
|NRXP||US Pharmaceuticals||US Market|
Return vs Industry: NRXP underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: NRXP underperformed the US Market which returned -18.5% over the past year.
|NRXP Average Weekly Movement||12.5%|
|Pharmaceuticals Industry Average Movement||11.0%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: NRXP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NRXP's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. Fundamentals Summary
|NRXP fundamental statistics|
Is NRXP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NRXP income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.67|
|Net Profit Margin||0.00%|
How did NRXP perform over the long term?See historical performance and comparison